Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1756-1761

  Ciardiello, F ^a   Normanno, N ^b   Maiello, E ^c   Martinelli, E ^a   Troiani, T ^a   Pisconti, S ^d   Giuliani, F ^e   Barone, C ^f   Carteni G ^g   Rachiglio, A M ^b   Montesarchio, V ^h   Tonini, G ⁱ   Rizzi, D ^e   Cinieri, S ^j   Bordonaro, R ^k   Febbraro, A ^l   de vita, F ^a   Orditura, M ^a   Fenizia, F ^b   Lambiase, M ^b   Rinaldi, A ^m   Tatangelo, F ^b   Botti, G ^b   Colucci, G ^e   more..

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d SS Annunziata Hospital   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h MONALDI HOSPITAL   (Italy)

ⁱ Unit of Hematology Stem Cell Transplantation   (Italy)

^j A Perrino Hospital   (Italy)

^k Garibaldi Central Hospital   (Italy)

^l Department of Radiology   (Italy)

^m Department of Medical Oncology Hospital Polo Occidentale   (Italy)

more..

Author keywords

BRAF; Cetuximab; Colorectal cancer; KSA NRAS; Next generation sequencing; PIK3CA

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; N RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; RAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EXON; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; ONCOGENE N RAS; PHARMACOGENETICS; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; CANCER TISSUE; FEASIBILITY STUDY; GENE MUTATION; GENETIC PROCEDURES; HUMAN TISSUE; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; NRAS GENE; OPEN STUDY; TP53 GENE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUCOVORIN; MEMBRANE PROTEINS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906846009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu230     Document Type: Article

References (18)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
2. Van Cutsem E, Köhne CE, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
3. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
4. Normanno N, Tejpar S, Morgillo F et al. Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
5. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet 2010; 11: 753-762.
6. Schwartzberg LS, Rivera F, Karthaus M et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 13(suppl 3): abstr 3631.
7. Stintzing S, Jung A, Rosssius L et al. Analisi of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of Folfiri plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur J Cancer 2013; 49(suppl 3): LBA17.
8. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287.
9. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28: 1181-1189.
10. De Roock W, De Vriendt V, Nomanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
11. Normanno N, Petraroli R, Rico A et al. The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers. AACR 2013; abstract 36.
12. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
13. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
14. Stintzing S, Jung A, Rossius L et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3. A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014; 32(suppl 3): abstr 445.
15. Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-4914.
16. Normanno N, Pinto C, Castiglione F et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One 2011; 6: e29146.
17. Bellon E, Ligtenberg MJ, Tejpar S et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011; 16: 467-478.
18. Gerlinger M, Rowan AJ, Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.